HELIX BIOPHARMA (HBP:TSE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HELIX BIOPHARMA (HBP:TSE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: thewiz who wrote (165)	11/13/1998 11:44:00 AM
From: burner	Read Replies (1) of 193

Biphasix presented to international scientists Helix Biopharma Corp HBP Shares issued 13,776,415 Nov 10 close $0.25 Wed 11 Nov 98 News Release An anonymous director reports The company's director of pharmaceutical research, Dr. Marianna Foldvari, will be presenting certain aspects of her research on the dermal and transdermal delivery of proteins using the Biphasix drug delivery system, at the American Association of Pharmaceutical Scientists annual meeting being held in San Francisco on Nov. 15 - 19. The Biphasix system is a unique, third generation, lipid-based microencapsulation delivery system which is capable of delivering a wide variety of pharmaceuticals of varying size, weight and solubility through the skin. Helix is concentrating its Biphasix development on the delivery of protein pharmaceuticals such as alpha interferon and insulin, as well as vaccines, via the dermal route with the objective of eliminating the need for injections. The company is actively promoting the Biphasix in Europe and North America to prospective commercial strategic partners to apply this technology to their existing compounds, as well as compounds under development.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next